Xeris Biopharma Reports Q2 2026 Financial Results

What Happened
On August 6, 2026, Xeris Biopharma Holdings, Inc. (XERS) filed a Form 8-K to announce its second quarter 2026 financial results and business highlights for the three- and six-month periods ended June 30, 2026. The company furnished a press release dated August 6, 2026 as Exhibit 99.1 to the Form 8-K. The filing was signed by Steven M. Pieper, Chief Financial Officer.

Key Details

• Filing date: August 6, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: three and six months ended June 30, 2026 (Q2 2026).
• Press release containing the results and business highlights is furnished as Exhibit 99.1.
• Form includes exhibit references under Item 9.01 (Exhibit 99.1 and Inline XBRL cover page).

Why It Matters
This 8-K signals that Xeris has publicly disclosed its Q2 2026 operating and financial updates—information investors use to assess revenue trends, profitability, cash position and near-term outlook. The Form 8-K itself furnishes the press release; investors should read the Exhibit 99.1 press release and the company's subsequent quarterly report (Form 10-Q) for the full numerical detail, management commentary and any guidance.